J&J Unit To Pay $5.9M To End Mont. Risperdal Row
Janssen Pharmaceutical Inc. agreed to the settlement without admitting to any wrongdoing, as part of a deal that prevents it from misleading consumers about its drugs in the future, according to a statement by the Montana AG’s office.
Roughly $1.5 million of the settlement funds...
To view the full article, register now.